PDCD1 and melanoma: This is attributed to the availability of novel therapies: multiple checkpoint inhibitors such as programmed cell death protein 1 (PD-1) as well as cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4) inhibitors and multiple tyrosine kinase inhibitors targeting BRAF–mutated melanoma [4].